Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer

Study limitation reported by the research below: “Sex not explicitly reported as female-only in the paper, but breast cancer context and no mention of male patients strongly implies a female cohort — tagged as female with low uncertainty.”